These medications contain a complete regimen all in one:

SINGLE-TABLET REGIMENS (Mutliple drug classes; see pregnancy information for integrase inhibitors below.)



Atripla RECOMMENDED INITIAL REGIMEN IN CERTAIN CLINICAL SITUATIONS

efavirenz/emtricitabine/tenofovir DF (EFV/FTC/TDF)

One tablet (600 mg efavirenz/200 mg emtricitabine/300 mg tenofovir DF), once daily. Take on an empty stomach, preferably at bedtime.



Complera ✓ RECOMMENDED INITIAL REGIMEN IN CERTAIN CLINICAL SITUATIONS IF VIRAL LOAD <100,000 COPIES/mL AND CD4 COUNT >200 CELL/mm³

rilpivirine/emtricitabine/tenofovir DF (RPV/FTC/TDF)

One tablet (25 mg rilpivirine/200 mg emtricitabine/300 mg tenofovir DF), once daily. Take with a meal.



RECOMMENDED INITIAL REGIMEN FOR MOST PEOPLE EXCEPT Dovato ★ THOSE WITH VIRAL LOAD >500,000 COPIES/mL, HBV CO-INFECTION, OR BEFORE RESULTS OF GENOTYPIC RESISTANCE OR HBV TESTING dolutegravir/lamivudine (DTG/3TC)

One tablet (50 mg dolutegravir/300mg lamivudine), once daily. Take with or without food.



Juluca recommended as continuation therapy for people with undetectable hiv viral load for at least 6 months

dolutegravir/rilpivirine (DTG/RPV)

One tablet (50 mg dolutegravir/25 mg rilpivirine), once daily. For adults who are virologically suppressed on a current ART regimen for at least 6 months and who have no history of treatment failure or resistance mutations associated with rilpivirine or dolutegravir. Take with a meal.



Stribild RECOMMENDED INITIAL REGIMEN IN CERTAIN CLINICAL SITUATIONS

elvitegravir/cobicistat/emtricitabine/tenofovir DF (EVG/COBI/FTC/TDF)

One tablet (150 mg elvitegravir/150 mg cobicistat/200 mg emtricitabine/ 300 mg tenofovir DF), once daily. Take with food.



RECOMMENDED INITIAL REGIMEN IN CERTAIN CLINICAL SITUATIONS

efavirenz/lamivudine/tenofovir DF (EFV/3TC/TDF)

One tablet (400 mg efavirenz/300 mg lamivudine/300 mg tenofovir DF), once daily. Should be taken on an empty stomach, preferably at bedtime.



Triumeq ★ RECOMMENDED INITIAL REGIMEN FOR MOST PEOPLE IF HLA-B*5701 NEGATIVE

daily. One additional 50 mg tablet of Tivicay 12 hours apart in people with viral resistance to INSTIs or when taken with certain other medications. Take with or without food.



Biktarvy ★ RECOMMENDED INITIAL REGIMEN

bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) One tablet (50 mg bictegravir/200 mg emtricitabine/25 mg tenofovir alafenamide), once daily. For adults who are treatment-naïve, or on treatment and virologically suppressed for at least 3 months, with no history of treatment failure or resistance mutations associated with components of Biktarvy. Take with or without food.



Delstrigo RECOMMENDED INITIAL REGIMEN IN CERTAIN CLINICAL SITUATIONS

doravirine/lamivudine/tenofovir DF (DOR/3TC/TDF)

One tablet (100 mg doravirine/300 mg lamivudine/300 mg tenofovir DF), once daily. Take with or without food.



Genvoya RECOMMENDED INITIAL REGIMEN IN CERTAIN CLINICAL SITUATIONS

elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (EVG/COBI/FTC/TAF)

One tablet (150 mg elvitegravir/150 mg cobicistat/200 mg emtricitabine/ 10 mg tenofovir alafenamide), once daily. Take with food.



RECOMMENDED INITIAL REGIMEN IN CERTAIN CLINICAL SITUATIONS IF VIRAL LOAD <100,000 COPIES/mL AND CD4 COUNT >200 CELL/mm³

rilpivirine/emtricitabine/tenofovir alafenamide (RPV/FTC/TAF)

One tablet (25 mg rilpivirine/200 mg emtricitabine/25 mg tenofovir alafenamide), once daily. Take with a meal.



Symfi RECOMMENDED INITIAL REGIMEN IN CERTAIN CLINICAL SITUATIONS

efavirenz/lamivudine/tenofovir DF (EFV/3TC/TDF)


One tablet (600 mg efavirenz/300 mg lamivudine/300 mg tenofovir DF), once daily. Should be taken on an empty stomach, preferably at bedtime.



Symtuza RECOMMENDED INITIAL REGIMEN IN CERTAIN CLINICAL SITUATIONS

darunavir/cobicistat/emtricitabine/tenofovir alafenamide (DRV/COBI/FTC/TAF)

One tablet (800 mg darunavir/150 mg cobicistat/200 mg emtricitabine/ 10 mg tenofovir alafenamide), once daily. Take with food.





cabotegravir/rilpivirine long-acting (CAB LA/RPV LA)

LONG-ACTING REGIMEN

NOT YET APPROVED AT PRESS TIME.

DHHS RECOMMENDATION NOT YET ESTABLISHED

Long-acting injection of 400 mg cabotegravir plus 600 mg rilpivirine every 4 or 8 weeks in studies. Dose in studies consisted of two 2 mL injections. Rilpivirine must be taken with food. Induction phase with oral medication used in research and will be used when approved. Cabotegravir lead-in dose tablet may not otherwise be available on the market.

PHOTO UNAVAILABLE